<unk> , sold under the brand name Cholbam, is approved for use in the United States and is indicated as a treatment for children and adults with bile acid synthesis disorders due to single enzyme defects, and for peroxisomal disorders (such as Zellweger syndrome). It was approved for use in the European Union in September 2013, and is sold under the brand name Orphacol. It is indicated for the treatment of inborn errors in primary bile-acid synthesis due to 3β-hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-oxosteroid-5β-reductase deficiency in infants, children and adolescents aged one month to 18 years and adults.<unk>  FGK (Kolbam) was approved for medical use in the European Union in November 2015. It is indicated for the treatment of inborn errors of primary bile acid synthesis, in infants from one month of age for continuous lifelong treatment through adulthood, encompassing the following single enzyme defects: * sterol 27-hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis, CTX); * 2- (or alpha-) methylacyl-CoA racemase (AMACR) deficiency; * cholesterol 7 alpha-hydroxylase (CYP7A1) deficiency. The most common side effects include peripheral neuropathy (nerve damage in the hands and feet), diarrhea, nausea (feeling sick), acid reflux (stomach acid flowing up into the mouth), esophagitis (inflammation of the food pipe), jaundice (yellowing of the skin and eyes), skin problems (lesions) and malaise (feeling unwell). Structure of<unk>  showing relationship to other bile acids
Cholic acid
Lipoic acid
Phytosterol
Omega-6 fatty acid
Omega-3 fatty acid
Conjugated linoleic acid
Fish oil
Fish oil 